Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Potential Clinical Benefits of TDM of Antimicrobials in Japan

Version 1 : Received: 18 January 2022 / Approved: 19 January 2022 / Online: 19 January 2022 (14:29:36 CET)

How to cite: Ebihara, F.; Hamada, Y.; Maruyama, T.; Kimura, T. Potential Clinical Benefits of TDM of Antimicrobials in Japan. Preprints 2022, 2022010277 (doi: 10.20944/preprints202201.0277.v1). Ebihara, F.; Hamada, Y.; Maruyama, T.; Kimura, T. Potential Clinical Benefits of TDM of Antimicrobials in Japan. Preprints 2022, 2022010277 (doi: 10.20944/preprints202201.0277.v1).

Abstract

Under the Japanese health insurance system, medicines undergoing therapeutic drug monitoring (TDM) can be billed for medical fees if they meet the specified requirements. In Japan, TDM of vancomycin, teicoplanin, aminoglycosides, and voriconazole, which are used for the treatment of infectious diseases, is common practice. This means the levels of antimicrobial agents are measured in-house using chromatography. This review describes personalized medicine based on the use of chromatography as a result of the current situation in Japan.

Keywords

HPLC; TDM; ceftriaxone; daptomycin; linezolid

Subject

MEDICINE & PHARMACOLOGY, Pharmacology & Toxicology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.